Literature DB >> 29906101

Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson's Disease.

Alice Biosa1, Irene Arduini1, Maria Eugenia Soriano1,2, Valentina Giorgio2, Paolo Bernardi2, Marco Bisaglia1, Luigi Bubacco1.   

Abstract

The preferential degeneration of dopaminergic neurons in the substantia nigra pars compacta is responsible for the motor impairment associated with Parkinson's disease. Dopamine is a highly reactive molecule, which is usually stored inside synaptic vesicles where it is stabilized by the ambient low pH. However, free cytosolic dopamine can auto-oxidize, generating reactive oxygen species, and lead to the formation of toxic quinones. In the present work, we have analyzed the mechanisms through which the dysfunction of dopamine homeostasis could induce cell toxicity, by focusing in particular on the damage induced by dopamine oxidation products at the mitochondrial level. Our results indicate that dopamine derivatives affect mitochondrial morphology and induce mitochondrial membrane depolarization, leading to a reduction of ATP synthesis. Moreover, our results suggest that opening of the mitochondrial transition pore induced by dopamine-derived quinones may contribute to the specific Parkinson's disease-associated vulnerability of dopamine containing neurons.

Entities:  

Keywords:  ATP synthase; Parkinson’s disease; dopamine; dopamine-derived quinones; mitochondria; permeability transition pore

Year:  2018        PMID: 29906101     DOI: 10.1021/acschemneuro.8b00276

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  8 in total

1.  Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells.

Authors:  Alice Biosa; Federica De Lazzari; Anna Masato; Roberta Filograna; Nicoletta Plotegher; Mariano Beltramini; Luigi Bubacco; Marco Bisaglia
Journal:  Neurotox Res       Date:  2019-06-21       Impact factor: 3.911

2.  The Therapeutic Implications of Tea Polyphenols Against Dopamine (DA) Neuron Degeneration in Parkinson's Disease (PD).

Authors:  Zhi Dong Zhou; Shao Ping Xie; Wuan Ting Saw; Patrick Ghim Hoe Ho; Hongyan Wang; Zhou Lei; Zhao Yi; Eng King Tan
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 3.  The bimodal mechanism of interaction between dopamine and mitochondria as reflected in Parkinson's disease and in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2019-12-17       Impact factor: 3.575

4.  6-Hydroxydopamine: a far from simple neurotoxin.

Authors:  Damir Varešlija; Keith F Tipton; Gavin P Davey; Andrew G McDonald
Journal:  J Neural Transm (Vienna)       Date:  2020-01-01       Impact factor: 3.575

Review 5.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

Review 6.  Are Proteinopathy and Oxidative Stress Two Sides of the Same Coin?

Authors:  Nihar J Mehta; Praneet Kaur Marwah; David Njus
Journal:  Cells       Date:  2019-01-16       Impact factor: 6.600

7.  Structural mechanism for tyrosine hydroxylase inhibition by dopamine and reactivation by Ser40 phosphorylation.

Authors:  María Teresa Bueno-Carrasco; Jorge Cuéllar; Marte I Flydal; César Santiago; Trond-André Kråkenes; Rune Kleppe; José R López-Blanco; Miguel Marcilla; Knut Teigen; Sara Alvira; Pablo Chacón; Aurora Martinez; José M Valpuesta
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

8.  Aqueous Extract of Davallia mariesii Attenuates 6-Hydroxydopamine-Induced Oxidative Damage and Apoptosis in B35 Cells Through Inhibition of Caspase Cascade and Activation of PI3K/AKT/GSK-3β Pathway.

Authors:  Chi-Rei Wu; Hung-Chi Chang; Yih-Dih Cheng; Wan-Cheng Lan; Shu-Er Yang; Hui Ching
Journal:  Nutrients       Date:  2018-10-06       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.